Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer

THURSDAY, April 1, 2021 -- Among patients with resected esophageal or gastroesophageal junction cancer who have received neoadjuvant chemoradiotherapy, disease-free survival is significantly longer with nivolumab adjuvant therapy versus placebo,...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

mas Schmidt Esophageal cancer is among the top ten most deadly cancers worldwide with adenocarcinomas of the esophagus showing increasing incidences over the last years. The prognosis is determined by tumor stage at diagnosis and in locally advanced stages by response to (radio-)chemotherapy followed by radical surgery. Less than a third of patients with esophageal adenocarcinomas completely respond to neoadjuvant therapies which urgently asks for further strategies to improve these rates. Aiming at the tumor microenvironment with novel targeted therapies can be one strategy to achieve this goal. This review connects e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
ConclusionsAdjuvant durvalumab in patients with residual disease in the surgical specimen following trimodality therapy for locally advanced esophageal and GEJ AC led to clinically meaningful improvement in 1-year RFS compared to historical control rate. Higher PD-L1 expression may have a correlation with the efficacy of durvalumab in this setting. Higher proportion of M2 macrophages and CD4 memory activated T cells was associated with superior RFS.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Evaluating the effect on primary lesions is important in determining treatment strategies for esophageal cancer. The Response Evaluation Criteria in Solid Tumors system, which employs the longest diameter for ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
ConclusionMIE seems oncologically safe and may even be better than the open approach in terms of LN harvest especially in patients with T1 and T2 tumors and in poor responders.
Source: Surgical Endoscopy - Category: Surgery Source Type: research
We examined the association of volume, program accreditation, safety net status, geographic region, patient travel distance on adequate adherence (≥85% of patients are adherent) using logistic regression modeling.RESULTS: The rate of adequate adherence was worst in nodal staging (12.6%) and highest for utilization of neoadjuvant therapy (84.8%). Academic programs had the highest rate of adequate adherence for induction therapy (77.2%, p
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Takashi Kamei Hironobu Sasano Necroptosis is a pivotal process in cancer biology; however, the clinical significance of necroptosis in esophageal squamous cell carcinoma (ESCC) has remained unknown. Therefore, in this study, we aimed to verify the potential involvement of necroptosis in the clinical outcome, chemotherapeutic resistance, and tumor microenvironment of ESCC. Mixed lineage kinase domain-like protein (MLKL) and phosphorylated MLKL (pMLKL) were immunohistochemically examined in 88 surgically resected specimens following neoadjuvant chemotherapy (NAC) and 53 pre-therapeutic biopsy specimens, respectively. T...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: In patients undergoing surgical resection for locally advanced adenocarcinoma of the GOJ, OS and DFS did not differ significantly between patients who had neoadjuvant chemoradiation compared with chemotherapy.PMID:34476473 | DOI:10.1093/bjs/znab228
Source: The British Journal of Surgery - Category: Surgery Authors: Source Type: research
We read with interest the systematic review and meta-analysis by Li et al1 comparing lower and higher radiation doses for operable esophageal/gastroesophageal junction carcinoma. This is a topical article, with several other recent systematic reviews and meta-analyses reporting on high-dose relative to low-dose chemoradiation therapy.2,3 In contrast to some other meta-analyses, the article by Li et al reports that neoadjuvant chemotherapy with low-dose radiation therapy may offer superior overall survival, progression-free survival, toxicity, and distant failure rates compared with high-dose radiation therapy.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Radiation Dose for Operable Esophageal/GEJ Cancer Source Type: research
We appreciate the opportunity to reply to the letter1 regarding  our manuscript.2 We strongly agree with the author's opinion concerning the reassessment of a preoperative radiation dose of more than 41.4 Gy for patients with operable esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ) receiving neoadjuvant concurrent chemoradiation therap y (nCRT) because of the uncertain benefit of an additional 5 to 10 Gy escalation. Two important randomized trials (CROSS and NEOCRTEC5010 trial) using 41.4 or 40 Gy demonstrated promising data regarding numerically non-inferior survival compared with>41.4 Gy radiation.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Gastroenterology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pharmaceuticals